Indaptus Therapeutics, Inc., a clinical stage biotechnology company, has announced the initiation of a Phase 1b/2 combination clinical trial involving their experimental therapy, Decoy20, in conjunction with the PD-1 checkpoint inhibitor, tislelizumab. This trial aims to evaluate the efficacy of this combination in inducing solid tumor regression in patients who have not responded to existing immunotherapies. The company has reported dosing the first patient in this trial and expects to present initial data from the first cohort of patients later this year. This development marks a significant step in Indaptus' ongoing efforts to advance innovative treatments for cancer and viral infections.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-023332), on August 13, 2025, and is solely responsible for the information contained therein.